pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-4745 |
Genomic Coordinates | chr19: 804940 - 805001 |
Description | Homo sapiens miR-4745 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | ||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-4745-5p | |||||||||||||||||||||||||||||||||||||||||||||
Sequence | 2| UGAGUGGGGCUCCCGGGACGGCG |24 | |||||||||||||||||||||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||||||||||||||||||||
Experiments | Illumina | DRVs in miRNA |
|
|||||||||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | GATAD2A | ||||||||||||||||||||
Synonyms | p66alpha | ||||||||||||||||||||
Description | GATA zinc finger domain containing 2A | ||||||||||||||||||||
Transcript | NM_017660 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on GATAD2A | |||||||||||||||||||||
3'UTR of GATAD2A (miRNA target sites are highlighted) |
>GATAD2A|NM_017660|3'UTR 1 TGCGAGCCAGGCCCCGTGGAAGACGGGCTCCCTCCTCCCCCACCTGGCCCCTGGTCTAGAAGGACCCACTGCACCACCCT 81 CCGCTGGCTCGGGAAGACACCGTGCCCGCCCCAAGAGCAAGCACCGGCCATGCTGCAGAGGCAAGACCTCAATTCTTGGC 161 TGCAAAGTTTCATCAGGGCTAGGGGGCTGGTGCCGCCTCATAGGCAGACGAGGATCATCGCTGGGGGACCTTTCCCGTGG 241 GCTTTCTTCCTTTCTCTCTTTGCCTTTAGTTTGCCCGACACCAGCAGAAAAGTGGACCTTGGGGGCTGGTTCTGCTCCTG 321 GCCCCCTTGTTCAGCCCCTGCCGGCACACGGGCGGCTCACCCTGGACACTGTGATGCGCATGGGCAAGGCCAGCGCCCGG 401 GGCTTCTGAACCGAGCGGGGTGTTTCATTTTTTTGCTTTTCCCTGTCTTAGGCTCCCAGTCTTTGACTGCCTTCCCATGG 481 CGATCTATAAGTTGAAAGATTTTTTTTTTTTTTAATCACCTCATGATGATGGAGTTAAAAGTAAACCGTGCAGACCCTGG 561 GGTCCCTGTTGTACGCTGCATCATCCCGCTGGCCCTGTGCCCTGGAGGGTGGGCGGCTCATGGTGCCACAGCCCCTGGCA 641 GGGACGGCCGGCCCGCCCCCGTGACTGACTGACAGATGCAGGGATGGCCGAGGCAGCCCTCGCTCCAGCTGAACGCCTCC 721 ATTGCTGCTTGTTCTGGAGACCCCCGCCCCCGCACCTTCCAGACTTAGCAGAAGAACAAACTGAAGAACAGACCCAGCCA 801 GAGAAGCAGGGATTCCAGAAGCTGCCCATTAAGGGAGAAGGAGAGGATCCGGTCGGCAGCAGCCCTGAGCAGAAAGCTGG 881 AGGGGGGACTGTCGCGGGGTTTTTCTGTTGTGGTTTATTTTATTAAATTTTTTCCTTTTTTCTATTCATTTCGATGGACG 961 CAATCTTAAGCCACCCTGGCCTTGCTCCTGGGAGGTGAGCGTGCACAGGTGTGTGCAGGTCAGGAGGTGCCGTCCAGGTG 1041 TGCGGCGAGCCGCTGCGCACAGATGTCAGGATTTCCGTTTGGGTCTAGTTTAGAACCTGTCCTTAAACCTAGGGGTTGCT 1121 GTCAGGATTTGCTTTCAGACTTTTTTTTTTTTTGTAATTCCCTTTAGAGTCTACAAAAATGTTTTTAAAAGGATCAGGTC 1201 TGCTTTTAGTTTCATTTTTGTTTCTTTCCCGTCCCACTCTTTAAAAACTGGTTCCGTGAGGAAAGGCAGAAGCCGTTCCG 1281 TGTCTCTTGCAGGCTGGGCCGGCTTCATGCCAGTGCGAGGGCGTCCCGTGCCCACGTACATACGTATGTCTCCATGAGTT 1361 CTGGGCTCCACTGGTTCCAATTGAGCTCCAGCCCTGGTTTTCCTACCCATGCAGTTAGGGACTTTAATTTAATTTTTTTT 1441 TTGTAGGGCCACCGCCTTCAAACACAACTGCTACAACATTCTAATAAAGGCTCATTTAACCCCCAGGCTCCTGTCGTGTG 1521 AATATCCTCAGTCTGTAGGAAACTTTTTTTGACACAGCATAGAAGACCTAGTTTTGGAAAACATTATCTAATTTTTTGTT 1601 GTGCAAATCCCCAAATTTCTCACTAATTTTTGTTTTTTTGTGCATAACTTGGATGGGCTGAAGGAGGTGAGGACAGATTG 1681 GGGAAGGGTGGCTTTCATTCCAAGATCCAGGGATTTGGGGAAAAGGAAGGAATTTGATGTTTTTTGGGGTGGGAGGGGAG 1761 GGTGTGTTTTTTACACCAAAAAAAAAAAAAAAAATCAAGAGTATGCAAGCATTTCTATTCCTCGCATTTTTCTGTGTGCC 1841 TGGCAAATAAATACCTGTCTCCTACGACCCTGAGCTGTTAGCCCTCTCTGTTCCATGACAGGGGCCAGATCTTCCAGCTC 1921 CTCCCAGAAGGAGCACCCAGGCTGGCTTCTTCCCACTGAAAGCCCTCCCCAGCGAACCAACCTCAGTTCTATGCAGTGGC 2001 TGGGGATCAGGCATCCAGACCGAAGTCACCTCTGCCTGCTCCAGCTTGGGTCAGCTGGGTCTGACCAGGGGGCCAGATCC 2081 GAGCCGCACCTGCCGGCCCCCAGCCCCAGCTCCAGCTCCTGACCTCTCCCAGCCTGGCCTGGCTGTTCCTCCAGGGCTGA 2161 TGGCTGTCAACCCATCCTTGTGAGTTCATATGGACTGCTGCCCCTCGAAAGGGAGAGGGTCGGCCCCATGTCCCCAGGGA 2241 GCATTCCATCAGGGACAACGTACATACTGTGATGTAAACTTTTTTTTTTTCCCCCCAGGGGGCAAAAGTGTGAGATGCCT 2321 TAATCTTTCCTTCATTTCTGCTGTCTCGAACACTCTAGCCCATTATTTCCTTTCAGTTCCTTGCAGCATAACCTCTACGA 2401 TAAGCCCCAAGCGGGTTGTTGTATTATGACGTTTATGATGTTCCAGGTGAAGGCATTATTAAGTACCTCTCTGGGTGTGG 2481 GGTTTGGACGCACCAGGATAGCTATTGATTAATGTTAAGGGTGTTCTACCCACAGCAAAGCACACCCTCTTAAACCAGGC 2561 ACTGCCTGGGTCCTGGTCCCGAGAGCCCTACCAGGATCAGGTTCCTGCAAGCCGTCAGAATGTGGGAGCCCCCAGCCCAA 2641 CTGATTGTAACTGTCCCCTGTTACCTGTGACATGAACCTCCAACAGCACCTGGAAACGGTTCCCTCTGTCAGCTGCTCTG 2721 TAGACAGGGCTGGGGAGATCTCAGAGTTCACACCTCGCCTGTTGTAGGGGAGGTTGGGGGTAGGGTTTGGAATGGCCAAG 2801 TGCCCTTGGAACCTCCCACAGCTATGGCCGTCCTGACCTCATCCCAGGAACTCTACGGTGACCAGGAACCACCCCTCTGA 2881 CGAGGTCTGTAGCGGCCCTTCTCAGAGTGGAACAGCCCACAGTGCTAGTTGTGCCTGGTCTTACCTGTACTCCACGGACC 2961 TCGGTGAAGCAAAAGCTTCAGGGCAGAGGGAATGAGGCAACCCAGTGGCAGCCCCGCTGGGCCCCGTGGCTCCTGCTCTC 3041 CTATTGGACGTAGAGGCAGGGGAGAGACTTCTCTATACAAATATTCTCATCACAGAAGGGATGATCCTTGCTGCTCTGCC 3121 GTAGGGTTTTTGATGCTGAGCTATGCTGCACATGACGTTAACCTAAAGAACTTGGACTGAGCTTTTAAAAAAGGACAGCA 3201 AACAATTTTATAATCCTTAAAGTGTAATAGACGGTTACACTAGTGCAGGGTATTGGGGAGGCTCTTTGGGTGTGGAGGCT 3281 GTCACTTGTATTTATTGTGACTCTAAATCTTTGATAGTAAAACAAATGTAAAAAGAAATGTTTGCCACCAGATGGGAATA 3361 GAAGTTCCAATAAGCAGGCTGGAATGGGTGGCTATACGTTGTATCACGAGGAAGTTTTAGACTCTGAAGGATAATAAATG 3441 GATGATGTGTCAACTGGAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | TZM-bl | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | Prostate Tissue | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRX1760638. RNA binding protein: AGO2. Condition:AGO-CLIP-PC3-miR148
... - Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al., 2016, Neoplasia (New York, N.Y.). |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Hamilton MP; Rajapakshe KI; Bader DA; Cerne et al. - Neoplasia (New York, N.Y.), 2016
MicroRNA (miRNA) deregulation in prostate cancer (PCa) contributes to PCa initiation and metastatic progression. To comprehensively define the cancer-associated changes in miRNA targeting and function in commonly studied models of PCa, we performed photoactivatable ribonucleoside-enhanced cross-linking immunoprecipitation of the Argonaute protein in a panel of PCa cell lines modeling different stages of PCa progression. Using this comprehensive catalogue of miRNA targets, we analyzed miRNA targeting on known drivers of PCa and examined tissue-specific and stage-specific pathway targeting by miRNAs. We found that androgen receptor is the most frequently targeted PCa oncogene and that miR-148a targets the largest number of known PCa drivers. Globally, tissue-specific and stage-specific changes in miRNA targeting are driven by homeostatic response to active oncogenic pathways. Our findings indicate that, even in advanced PCa, the miRNA pool adapts to regulate continuing alterations in the cancer genome to balance oncogenic molecular changes. These findings are important because they are the first to globally characterize miRNA changes in PCa and demonstrate how the miRNA target spectrum responds to staged tumorigenesis.
LinkOut: [PMID: 27292025]
|
CLIP-seq Support 1 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000360315.3 | 3UTR | UUUCUUUCCCGUCCCACUCUUUAAAAACUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
85 hsa-miR-4745-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT100716 | TJAP1 | tight junction associated protein 1 | 2 | 2 | ||||||||
MIRT183592 | ZC3H11A | zinc finger CCCH-type containing 11A | 2 | 2 | ||||||||
MIRT338035 | DAZAP2 | DAZ associated protein 2 | 2 | 4 | ||||||||
MIRT395801 | SPCS3 | signal peptidase complex subunit 3 | 2 | 2 | ||||||||
MIRT443946 | LRIT3 | leucine rich repeat, Ig-like and transmembrane domains 3 | 2 | 2 | ||||||||
MIRT450579 | HIST1H2BG | histone cluster 1 H2B family member g | 2 | 6 | ||||||||
MIRT451616 | MEIS3P1 | Meis homeobox 3 pseudogene 1 | 2 | 2 | ||||||||
MIRT452330 | EIF5AL1 | eukaryotic translation initiation factor 5A-like 1 | 2 | 2 | ||||||||
MIRT453278 | EFTUD2 | elongation factor Tu GTP binding domain containing 2 | 2 | 2 | ||||||||
MIRT455213 | GNL1 | G protein nucleolar 1 (putative) | 2 | 2 | ||||||||
MIRT455469 | LYPLA2 | lysophospholipase II | 2 | 2 | ||||||||
MIRT456502 | PFKFB2 | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 | 2 | 2 | ||||||||
MIRT456686 | LDB1 | LIM domain binding 1 | 2 | 2 | ||||||||
MIRT456914 | DDA1 | DET1 and DDB1 associated 1 | 2 | 2 | ||||||||
MIRT457602 | IDS | iduronate 2-sulfatase | 2 | 2 | ||||||||
MIRT457849 | RNASEH2B | ribonuclease H2 subunit B | 2 | 4 | ||||||||
MIRT458454 | RPRM | reprimo, TP53 dependent G2 arrest mediator homolog | 2 | 2 | ||||||||
MIRT460178 | UNK | unkempt family zinc finger | 2 | 6 | ||||||||
MIRT461464 | SLC19A3 | solute carrier family 19 member 3 | 2 | 2 | ||||||||
MIRT464738 | UBE2Q1 | ubiquitin conjugating enzyme E2 Q1 | 2 | 2 | ||||||||
MIRT465278 | TRIM28 | tripartite motif containing 28 | 2 | 2 | ||||||||
MIRT468449 | SETD1B | SET domain containing 1B | 2 | 2 | ||||||||
MIRT468619 | SUMO1 | small ubiquitin-like modifier 1 | 2 | 6 | ||||||||
MIRT469151 | RNF121 | ring finger protein 121 | 2 | 2 | ||||||||
MIRT470072 | PTGES2 | prostaglandin E synthase 2 | 2 | 2 | ||||||||
MIRT470171 | PSMD11 | proteasome 26S subunit, non-ATPase 11 | 2 | 4 | ||||||||
MIRT473155 | MLLT1 | MLLT1, super elongation complex subunit | 2 | 2 | ||||||||
MIRT474307 | LAMC1 | laminin subunit gamma 1 | 2 | 2 | ||||||||
MIRT474781 | KIAA0895L | KIAA0895 like | 2 | 2 | ||||||||
MIRT476482 | GATAD2A | GATA zinc finger domain containing 2A | 2 | 2 | ||||||||
MIRT477612 | EFNA3 | ephrin A3 | 2 | 2 | ||||||||
MIRT479523 | CDCA4 | cell division cycle associated 4 | 2 | 2 | ||||||||
MIRT479972 | CARD10 | caspase recruitment domain family member 10 | 2 | 2 | ||||||||
MIRT480409 | C19orf47 | chromosome 19 open reading frame 47 | 2 | 2 | ||||||||
MIRT480425 | C17orf85 | nuclear cap binding subunit 3 | 2 | 2 | ||||||||
MIRT483571 | SYT2 | synaptotagmin 2 | 2 | 2 | ||||||||
MIRT483663 | QSOX2 | quiescin sulfhydryl oxidase 2 | 2 | 4 | ||||||||
MIRT484531 | POLD3 | DNA polymerase delta 3, accessory subunit | 2 | 2 | ||||||||
MIRT484614 | SIX3 | SIX homeobox 3 | 2 | 6 | ||||||||
MIRT485896 | ZFP36 | ZFP36 ring finger protein | 2 | 2 | ||||||||
MIRT486504 | MYH11 | myosin heavy chain 11 | 2 | 2 | ||||||||
MIRT487506 | GRK5 | G protein-coupled receptor kinase 5 | 2 | 2 | ||||||||
MIRT488851 | UBTF | upstream binding transcription factor, RNA polymerase I | 2 | 2 | ||||||||
MIRT489463 | MSC | musculin | 2 | 2 | ||||||||
MIRT491168 | LRP3 | LDL receptor related protein 3 | 2 | 2 | ||||||||
MIRT496626 | TMEM67 | transmembrane protein 67 | 2 | 2 | ||||||||
MIRT497615 | ANG | angiogenin | 2 | 2 | ||||||||
MIRT497765 | KIAA0895 | KIAA0895 | 2 | 2 | ||||||||
MIRT499679 | MRE11A | MRE11 homolog, double strand break repair nuclease | 2 | 6 | ||||||||
MIRT499772 | SLC29A2 | solute carrier family 29 member 2 | 2 | 2 | ||||||||
MIRT501744 | NSD1 | nuclear receptor binding SET domain protein 1 | 2 | 2 | ||||||||
MIRT504993 | ZNF652 | zinc finger protein 652 | 2 | 2 | ||||||||
MIRT511663 | HIST1H3C | histone cluster 1 H3 family member c | 2 | 2 | ||||||||
MIRT511689 | HIST1H2BO | histone cluster 1 H2B family member o | 2 | 4 | ||||||||
MIRT511702 | HIST1H2BL | histone cluster 1 H2B family member l | 2 | 4 | ||||||||
MIRT511733 | HIST1H2BE | histone cluster 1 H2B family member e | 2 | 8 | ||||||||
MIRT512857 | TBC1D13 | TBC1 domain family member 13 | 2 | 2 | ||||||||
MIRT513443 | EMP1 | epithelial membrane protein 1 | 2 | 6 | ||||||||
MIRT515680 | TFPI | tissue factor pathway inhibitor | 2 | 2 | ||||||||
MIRT523528 | GLUL | glutamate-ammonia ligase | 2 | 2 | ||||||||
MIRT525545 | PHB2 | prohibitin 2 | 2 | 4 | ||||||||
MIRT526208 | SNX24 | sorting nexin 24 | 2 | 2 | ||||||||
MIRT531555 | SRD5A1 | steroid 5 alpha-reductase 1 | 2 | 2 | ||||||||
MIRT533763 | TMEM135 | transmembrane protein 135 | 2 | 2 | ||||||||
MIRT545581 | SNRPA1 | small nuclear ribonucleoprotein polypeptide A' | 2 | 2 | ||||||||
MIRT552433 | ZNF460 | zinc finger protein 460 | 2 | 2 | ||||||||
MIRT561158 | BCL2L12 | BCL2 like 12 | 2 | 2 | ||||||||
MIRT562344 | EXOSC2 | exosome component 2 | 2 | 2 | ||||||||
MIRT570658 | KDM6B | lysine demethylase 6B | 2 | 2 | ||||||||
MIRT571075 | TCHHL1 | trichohyalin like 1 | 2 | 2 | ||||||||
MIRT571331 | TPCN2 | two pore segment channel 2 | 2 | 2 | ||||||||
MIRT571601 | TOB2 | transducer of ERBB2, 2 | 2 | 2 | ||||||||
MIRT573012 | RPP25 | ribonuclease P and MRP subunit p25 | 2 | 2 | ||||||||
MIRT609042 | EP300 | E1A binding protein p300 | 2 | 2 | ||||||||
MIRT613397 | DNAH17 | dynein axonemal heavy chain 17 | 2 | 2 | ||||||||
MIRT635588 | TTC9C | tetratricopeptide repeat domain 9C | 2 | 2 | ||||||||
MIRT644753 | TXNRD3NB | thioredoxin reductase 3 neighbor | 2 | 2 | ||||||||
MIRT661117 | FPR1 | formyl peptide receptor 1 | 2 | 2 | ||||||||
MIRT690102 | PNMA2 | paraneoplastic Ma antigen 2 | 2 | 2 | ||||||||
MIRT694971 | PLAC8 | placenta specific 8 | 2 | 2 | ||||||||
MIRT695514 | ALPI | alkaline phosphatase, intestinal | 2 | 2 | ||||||||
MIRT695576 | ASB16 | ankyrin repeat and SOCS box containing 16 | 2 | 2 | ||||||||
MIRT699569 | SIT1 | signaling threshold regulating transmembrane adaptor 1 | 2 | 2 | ||||||||
MIRT701990 | MIER3 | MIER family member 3 | 2 | 2 | ||||||||
MIRT725462 | GRAP2 | GRB2-related adaptor protein 2 | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|